.START 

ImmunoGen Inc. said it filed with the Securities and Exchange Commission a registration statement proposing an initial public offering of 1.5 million common shares. 

The offering will be underwritten by a syndicate represented by PaineWebber Inc. and Hambrecht & Quist Inc. Proceeds are expected to be used for expenditures relating to product research and development, preclinical and clinical testing programs, expansion of manufacturing capacity, working capital and general corporate purposes. 

ImmunoGen develops pharmaceuticals for cancer treatment. 

